GlassScriptPhysician profile
Sofi M Abraham
NPI 1578097200
$5,297.23
in general payments reported to CMS, 2019-2025
64 companies · $739 in 2025
The $739 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,192 · 2022: $1,628 · 2023: $762 · 2024: $976 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,962 · Education: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,962.40 |
| Education | $514.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $455.16 | 2021-2024 | Rybrevant, Talvey, Tecvayli |
| Pfizer INC. | $432.80 | 2021-2025 | |
| Novo Nordisk INC | $291.00 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $249.79 | 2021-2025 | Evenity, Nplate, Xgeva |
| Glaxosmithkline, LLC. | $246.22 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $235.59 | 2021-2025 | Datroway, Fasenra, Airsupra |
| Seagen INC. | $231.16 | 2021-2025 | |
| Abbvie INC. | $197.07 | 2021-2025 | Vraylar |
| Exelixis INC. | $182.46 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.93 | 2023-2025 | Jardiance |
| Genzyme Corporation | $164.96 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $141.58 | 2022-2023 | |
| Lilly USA, LLC | $124.90 | 2022-2024 | Mounjaro |
| Pharmacyclics LLC, An Abbvie Company | $123.95 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $114.09 | 2022-2024 | Eliquis |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofi Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.